Molecular Partners AG Files Q3 2025 Financials
Ticker: MOLN · Form: 6-K · Filed: Oct 30, 2025 · CIK: 1745114
Sentiment: neutral
Topics: financial-statements, quarterly-report
TL;DR
MPRS dropped Q3 financials, check the numbers.
AI Summary
Molecular Partners AG filed a Form 6-K on October 30, 2025, to furnish a press release and unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2025. The filing includes financial data and accompanying notes.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Molecular Partners AG, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant strategic shifts.
Key Players & Entities
- Molecular Partners AG (company) — Registrant
- 001-40488 (company) — Commission File Number
- September 30, 2025 (date) — Reporting period end date
- October 30, 2025 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to furnish a press release issued on October 30, 2025, and the unaudited condensed consolidated interim financial statements as of and for the three and nine months ended September 30, 2025.
What period do the furnished financial statements cover?
The furnished financial statements cover the three and nine months ended September 30, 2025.
When was the press release mentioned in the filing issued?
The press release mentioned in the filing was issued on October 30, 2025.
What is the Commission File Number for Molecular Partners AG?
The Commission File Number for Molecular Partners AG is 001-40488.
Does Molecular Partners AG file annual reports under Form 20-F or Form 40-F?
Molecular Partners AG files annual reports under Form 20-F, as indicated by the checkmark next to it in the filing.
Filing Stats: 3,161 words · 13 min read · ~11 pages · Grade level 14.7 · Accepted 2025-10-30 16:00:23
Filing Documents
- q32025financialstatements.htm (6-K) — 243KB
- prq32025forsecfiling.htm (EX-99.1) — 35KB
- image_0.jpg (GRAPHIC) — 19KB
- 0001745114-25-000037.txt ( ) — 305KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Partners AG (Registrant) Date October 30, 2025 s PATRICK AMSTUTZ Name Patrick Amstutz Title Chief Executive Officer Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of September 30, 2025 December 31, 2024 in CHF thousands Note Assets Property, plant and equipment 3,185 4,198 Intangible assets 5 49 Total non-current assets 3,190 4,247 Short-term time deposits 22,162 85,565 Other current assets 2,335 2,525 Trade and other receivables 2,103 2,317 Cash and cash equivalents 82,359 63,874 Total current assets 108,960 154,281 Total assets 112,150 158,528 Shareholders' equity and liabilities Share capital 5.2 4,037 4,036 Additional paid-in capital 388,209 384,875 Treasury share reserve 5.2 (1,129) (981) Cumulative losses (295,588) (246,293) Total shareholders' equity 95,529 141,636 Trade and other payables 160 — Lease liability 308 1,227 Employee benefits 5.8 4,410 4,879 Total non-current liabilities 4,879 6,106 Trade and other payables 2,123 1,859 Accrued expenses 8,395 7,709 Lease liability 1,224 1,217 Total current liabilities 11,742 10,786 Total liabilities 16,621 16,892 Total shareholders' equity and liabilities 112,150 158,528 See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements. Condensed consolidated interim statement of profit or loss and other comprehensive result for the 9 months ended September 30, 2025 2024 in CHF thousands Note Revenues and other income Revenues from research and development collaborations 5.1 — 4,970 Total revenues and other income — 4,970 Operating expenses Research and development expenses (30,954) (38,055) Selling, general a